Last reviewed · How we verify
NCT05491720
Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder
Phase 1 trial testing RisperiDONE 1 MG/ML in Autism Spectrum Disorder in 45 participants. Completed in 3 August 2022.
15 March 2022
Quick facts
| Lead sponsor | The National Brain Mapping Laboratory (NBML) |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 15 August 2020 |
| Primary completion | 15 March 2022 |
| Estimated completion | 3 August 2022 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- RisperiDONE 1 MG/ML — full drug profile →
- transcranial direct current stimulation
- Placebo
- sham transcranial direct current stimulation
Conditions studied
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Sponsor
The National Brain Mapping Laboratory (NBML) — full company profile →
Who can join
Adults 7 to 16, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to comparing the effectiveness of transcranial direct current stimulation with common pharmacological treatments on behavioral problems and cognitive deficits of children with autism spectrum disorder
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05491720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autism Spectrum Disorder
Currently open trials in the same condition.
- NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
- NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting
Other The National Brain Mapping Laboratory (NBML) trials
Trials by the same sponsor.
- NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
- NCT06740864 — 40 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations · NA · completed
- NCT06401928 — Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis · NA · completed
- NCT06155786 — Cognitive Effects of tDCS and tRNS in Schizophrenia · NA · completed
- NCT05200962 — Electrical Brain Stimulation for Cognitive Impairment in Schizophrenia: a tDCS-fMRI Study · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05491720 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The National Brain Mapping Laboratory (NBML)
- Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing